ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Convalescent Plasma for Patients With Severe Coronavirus Disease 2019 (COVID-19): A Matched Cohort Study.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022Pooled it
- Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics.Reviews in medical virology · 2021Pooled it
- CONVALESCENT plasma for COVID-19: A meta-analysis of clinical trials and real-world evidence.European journal of clinical investigation · 2021Pooled it
- Efficacy of convalescent plasma therapy for COVID-19: A systematic review and meta-analysis.Journal of clinical apheresis · 2021Pooled it
- The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis.Mayo Clinic proceedings · 2021Pooled it
- Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.JMIR public health and surveillance · 2021Pooled it
- Convalescent plasma may be a possible treatment for COVID-19: A systematic review.International immunopharmacology · 2021Pooled it
- Mortality Benefit of Convalescent Plasma in COVID-19: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Impact of serological and PCR testing requirements on the selection of COVID-19 convalescent plasma donors.Transfusion · 2021Trial
- Serial Convalescent Plasma Infusions for the Initial COVID-19 Infections in the Appalachian Region of West Virginia.Allergy & rhinology (Providence, R.I.)Trial
- Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis.Mayo Clinic proceedings. Innovations, quality & outcomes · 2023Article
- How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?Stem cell reviews and reports · 2023Review
- Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review.Journal of blood medicine · 2023Review
- Convalescent human IgG, but not IgM, from COVID-19 survivors confers dose-dependent protection against SARS-CoV-2 replication and disease in hamsters.Frontiers in immunology · 2023Article
- Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.Transfusion · 2022Article
- COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes.Clinical microbiology reviews · 2022Review
- [Diagnosis and treatment of COVID-19 in intensive care units].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2022Review
- Convalescent plasma therapy in patients with severe COVID-19, A single-arm, retrospective study.Microbial pathogenesis · 2022Observational
- Multi-center matched cohort study of convalescent plasma for hospitalized patients with COVID-19.PloS one · 2022Article
- Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19.The Journal of clinical investigation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe efficacy of convalescent plasma (CP) for the treatment of coronavirus disease 2019 (COVID-19) remains unclear.
methodsIn a matched cohort analysis of hospitalized patients with severe COVID-19, the impact of CP treatment on in-hospital mortality was evaluated using univariate and multivariate Cox proportional-hazards models, and the impact of CP treatment on time to hospital discharge was assessed using a stratified log-rank analysis.
resultsIn total, 64 patients who received CP a median of 7 days after symptom onset were compared to a matched control group of 177 patients. The incidence of in-hospital mortality was 12.5% and 15.8% in the CP and control groups, respectively (P = .52). There was no significant difference in the risk of in-hospital mortality between the 2 groups (adjusted hazard ratio [aHR] 0.93, 95% confidence interval [CI] .39-2.20). The overall rate of hospital discharge was not significantly different between the 2 groups (rate ratio [RR] 1.28, 95% CI .91-1.81), although there was a significantly increased rate of hospital discharge among patients 65-years-old or greater who received CP (RR 1.86, 95% CI 1.03-3.36). There was a greater than expected frequency of transfusion reactions in the CP group (2.8% reaction rate observed per unit transfused).
conclusionsWe did not demonstrate a significant difference in risk of mortality or rate of hospital discharge between the CP and control groups. There was a signal for improved outcomes among the elderly, and further adequately powered randomized studies should target this subgroup when assessing the efficacy of CP treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.